A national analysis of adults diagnosed with lung cancer has exposed a striking weakness in the United States’ strategy for finding the disease early: many patients who ultimately develop lung cancer do not qualify for screening under current rules, and most do not receive a low-dose scan before their diagnosis. The study, based on the 2024 National Health Interview Survey, found that only about half of adults with lung cancer met the eligibility criteria recommended by the US Preventive Services Task Force (USPSTF) at the time they were diagnosed. Even more unexpectedly, just one-third reported undergoing low-dose computed tomography, or LDCT, before their cancer was found. The findings suggest that the problem is not simply that people fail to use an available test. The rules themselves may overlook substantial numbers of people at risk, while practical and clinical barriers prevent many eligible individuals from being screened.

Lung cancer is the third most commonly diagnosed cancer in the United States and remains the country’s leading cause of cancer-related death. Its danger is closely tied to timing: tumors discovered after they have spread are much harder to treat successfully, whereas earlier-stage disease may be removed surgically or treated with curative intent. LDCT is designed to detect small abnormalities before symptoms appear. Unlike a conventional diagnostic CT scan, which may cover a broader clinical question and use a higher radiation dose, LDCT uses a carefully calibrated, lower amount of radiation to create images of the lungs. Evidence from the National Lung Screening Trial showed that screening high-risk people with LDCT reduced lung-cancer mortality by about 20 percent compared with chest radiography. Yet the test is useful only if people at elevated risk are identified and return for regular examinations, and if suspicious findings are rapidly evaluated without causing unnecessary invasive procedures.

Under the 2021 USPSTF recommendations, adults between 50 and 80 years old should receive annual LDCT if they currently smoke or quit within the previous 15 years and have accumulated at least 20 “pack-years” of smoking. A pack-year represents smoking one pack of cigarettes per day for one year; someone who smoked two packs daily for 10 years, for example, would have 20 pack-years. The 2021 update lowered the minimum age from 55 to 50 and reduced the smoking threshold from 30 to 20 pack-years, expanding the population eligible for screening. The criteria were intended to improve access and address disparities, but they remain largely dependent on age and cumulative smoking exposure. That creates a blind spot for people who develop lung cancer after lighter smoking histories, long periods since quitting, or no history of smoking at all.

Researchers from the University of California, Irvine, retrospectively examined survey responses from 115 adults aged 50 or older who reported a lung-cancer diagnosis within the previous 10 years. After applying the survey’s statistical weights, the group represented an estimated 638,702 US adults. The analysis used smoking histories to determine whether each person would have qualified for LDCT under the 2021 USPSTF rules at the time of diagnosis. Smoking information was incomplete for four participants, or 3.5 percent of the sample, meaning their eligibility could not be determined. Among the remaining 111 people, 58—52.3 percent in the unweighted sample and approximately 52.0 percent after weighting—met the screening criteria. When people who had never smoked were excluded, eligibility rose to 64.4 percent, or about 66.3 percent using weighted estimates. Even that higher figure means that roughly one in three patients with a smoking history would not have qualified under the current rules.

The study also revealed a sharp difference between having received a CT scan at some point and having received a true screening scan before cancer was diagnosed. Overall, 92 of 110 respondents, or 83.6 percent, said they had undergone LDCT at some time. But only 36 people, or 32.7 percent, reported receiving the scan before their lung-cancer diagnosis; the weighted estimate was 29.6 percent. This distinction matters because CT imaging can be ordered for many reasons, including investigating coughing, chest pain, infection, trauma, or another medical condition. It can also be performed to monitor a known cancer. Such scans may reveal a tumor, but they are not equivalent to systematic screening of people without symptoms. The gap between the two figures therefore suggests that a large share of the imaging reported by patients was diagnostic or follow-up care rather than preventive screening.

The analysis found that women had substantially lower odds of meeting eligibility criteria than men. In the adjusted statistical model, the odds ratio for female sex was 0.31, with a 95 percent confidence interval from 0.12 to 0.77. In practical terms, the result reflects the fact that women in the study generally had accumulated fewer pack-years and had stopped smoking longer ago than men. Women also made up a much larger share of patients who had never smoked: 76.2 percent of never-smokers with lung cancer were female, compared with 43.3 percent among participants with a history of smoking. The researchers observed a possible disparity for non-White participants as well, with an odds ratio of 0.35, although the result narrowly missed conventional statistical significance. When never-smokers were removed from the analysis, demographic factors were no longer significantly associated with eligibility, suggesting that smoking patterns—and the higher proportion of women among never-smokers—helped drive the apparent sex difference.

The findings highlight a biological and epidemiological challenge that fixed smoking thresholds cannot fully address. Cigarette smoking remains the dominant preventable cause of lung cancer, but it is not the only pathway to the disease. Some tumors arise in people who never smoked, including groups in which lung cancer among never-smokers appears to be increasing or is already disproportionately common. Asian women who have never smoked, for instance, have been identified in previous research as an emerging population with elevated risk. Other contributors can include secondhand smoke, occupational exposures, radon, air pollution, inherited susceptibility, and chronic lung inflammation. A rule based only on age and pack-years may therefore be efficient for identifying a major high-risk group while still missing individuals whose risk is clinically meaningful but distributed across several factors. The study’s authors argue that the results add to evidence that current criteria do not capture everyone who will eventually develop lung cancer.

Why eligible people fail to complete screening is less clear from the survey. No demographic characteristic examined by the researchers was significantly associated with receiving LDCT before diagnosis. The reasons may lie in a complicated chain of obstacles: clinicians may not identify eligible patients, patients may not understand that screening is recommended before symptoms appear, and health systems may lack the staff or infrastructure to arrange annual scans and follow-up. Cost, insurance coverage, transportation, time away from work, fear of radiation, stigma surrounding smoking, and anxiety about a possible cancer diagnosis can all reduce participation. Primary-care providers may also be uncertain about the detailed eligibility rules or may prioritize other urgent health needs. Screening is not a one-time event but a recurring process, so a program must maintain contact with patients and ensure that abnormal results are tracked. A single missed appointment can break that chain.

The researchers caution that their estimates should not be interpreted as a perfect measure of screening performance. The survey relied on participants’ memories of their smoking histories, the timing of scans, and the type of CT imaging they received. People may not distinguish an LDCT screening examination from a diagnostic CT performed after symptoms developed, which could make screening uptake appear higher than it truly was. Conversely, incomplete recall of smoking may cause some people to be classified incorrectly as ineligible. The study was cross-sectional and used information collected after diagnosis, so it cannot establish why screening did or did not occur. Because only one year of survey data was analyzed, some racial, ethnic, and language groups were represented by very small numbers, preventing reliable comparisons. Demographic and socioeconomic characteristics such as insurance, income, employment, and residence may also have changed between diagnosis and survey completion, limiting the ability to connect them to earlier screening decisions.

Risk-based screening models could offer one possible way forward. Instead of relying on age and pack-years alone, these models estimate an individual’s probability of developing lung cancer using multiple variables, potentially including smoking intensity, time since quitting, chronic obstructive pulmonary disease, family history, body characteristics, socioeconomic conditions, and other clinical factors. Such approaches might identify some people who fall outside the USPSTF thresholds, including those with lower smoking exposure or additional non-smoking risks. But they also introduce new complications: the necessary data may be missing from medical records, risk calculations can be difficult to explain, and adding more inputs may make programs harder to implement consistently. For now, the new analysis points to a two-part public-health emergency. Screening systems must do a better job reaching people who already qualify, while researchers and policymakers must determine whether eligibility rules should evolve beyond smoking and age. Until both problems are addressed, many lung cancers may continue to be discovered only after the window for the simplest and most effective treatment has begun to close.

Subject of Research: Lung cancer screening eligibility and low-dose computed tomography completion among US adults diagnosed with lung cancer

Article Title: Lung cancer screening eligibility and completion among adults diagnosed with lung cancer: retrospective analysis of 2024 National Health Interview Survey

Article References: Zanazanian I, Chieh AYC, Madan A, et al. “Lung cancer screening eligibility and completion among adults diagnosed with lung cancer: retrospective analysis of 2024 National Health Interview Survey.” Cancer Causes & Control 37, article 148 (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02229-x

Keywords: lung cancer screening, low-dose CT, USPSTF guidelines, screening eligibility, health disparities, smoking history, early cancer detection, never-smokers

One of the foremost hurdles in this domain is the identification of precise risk factors that drive LCINS pathology. Unlike smokers, where exposure to carcinogenic tobacco smoke provides a clear etiological basis, never-smokers lack this obvious causative agent, complicating risk stratification and prevention efforts. Contemporary studies underscore an array of potential contributors including inherited germline mutations, environmental exposures such as prolonged inhalation of radon gas, ambient air pollution particulates, second-hand tobacco smoke, and even occupational radiation. Investigations into these drivers are facilitated by large-scale genomic and epidemiological analyses that have begun to elucidate polymorphisms in genes regulating DNA repair, cellular proliferation, and inflammatory responses. This molecular insight is critical to discerning which subpopulations among never-smokers might possess an elevated predisposition to develop lung malignancies despite the absence of personal smoking history.

Clinically, LCINS often manifests with subtle, nonspecific symptoms such as chronic cough, unexplained fatigue, and dysphagia, symptoms easily misattributed to benign respiratory or digestive conditions. This symptom ambiguity poses a diagnostic conundrum. Physicians and patients alike fail to associate these warning signs with cancer, especially within a framework that traditionally correlates lung neoplasms with smoking. Consequently, diagnostic imaging and specialist referrals are frequently delayed, resulting in late-stage tumor discovery when curative treatment options, like surgical resection or targeted therapies, are less effective or no longer viable. Enhancing awareness that never-smokers remain vulnerable to lung cancer is imperative to prompt timely clinical suspicion, earlier diagnostic interventions such as low-dose computed tomography (LDCT), and personalized screening protocols tailored to this subgroup, potentially transforming disease trajectories.

The biological landscape of LCINS diverges markedly from that of smoking-associated lung cancers at the molecular level. A distinctive feature is the predominance of adenocarcinoma histology within LCINS cases. Genomic profiling reveals that tumors in never-smokers harbor specific “driver” oncogenic mutations — notably mutations in the epidermal growth factor receptor (EGFR) gene and fusion events involving anaplastic lymphoma kinase (ALK) — which are amenable to targeted small-molecule inhibitors. These molecular therapeutic targets have revolutionized treatment paradigms for LCINS, offering enhanced efficacy with fewer side effects compared to conventional chemotherapy. Concomitantly, LCINS tumors exhibit a lower burden of somatic mutations, correlating with diminished responsiveness to immunotherapies such as immune checkpoint inhibitors that have shown promise in high-mutation burden cancers. These findings highlight the necessity of refining therapeutic regimens for never-smoker patients based on their unique tumor biology.

Screening initiatives have conventionally concentrated on individuals with substantial smoking histories, using criteria such as pack-years to define eligibility for lung cancer screening programs. However, the rising LCINS incidence underlines the inadequacy of such frameworks. Emerging research aims to establish evidence-based screening algorithms for never-smokers, integrating genetic risk profiling, environmental exposure assessments, and biomarkers to stratify risk and optimize screening frequency and modalities. Implementing such targeted screening measures promises to identify early-stage LCINS cases, vastly improving potential outcomes through timely intervention and reducing mortality.

Preventive strategies for LCINS extend beyond early detection to encompass novel approaches addressing inherited predispositions and environmental modifiers. Efforts are underway to characterize germline variants conferring susceptibility, paving the way for genetic counseling and potentially prophylactic interventions for high-risk individuals. Moreover, a growing body of work emphasizes the role of chronic inflammation — driven by pollutants, clonal hematopoiesis of indeterminate potential (CHIP), and inflammatory disorders — in lung carcinogenesis, inspiring exploration of anti-inflammatory agents as chemopreventive modalities. Public health policies targeting minimization of radon exposure, reduction of ambient air pollution, and elimination of second-hand smoke in public and private domains also constitute critical components of comprehensive LCINS prevention.

The complexity of LCINS necessitates an integrated research framework combining molecular oncology, epidemiology, environmental science, and clinical medicine. Forward-looking clinical trials are in development to test interventions ranging from personalized screening to pharmacological prevention and novel targeted therapeutics. These trials aim to balance efficacy with minimizing harms in never-smoker populations, ensuring that benefits of early detection and intervention decisively outweigh risks such as overdiagnosis and treatment-related toxicity.

Given the rising global prevalence of LCINS and its distinct pathogenesis relative to tobacco-related disease, researchers argue for an expanded awareness campaign targeted both at clinicians and the general public. Educating about the fact that ‘never-smoker’ status does not equate to ‘no risk’ could transform clinical practice, reduce diagnosis latency, and stimulate funding and policy support for this emerging public health concern. The cumulative impact of these multidisciplinary efforts promises to shift the landscape of lung cancer from reactive treatment toward proactive prevention and precise early intervention.

In summary, lung cancer in never-smokers has transitioned from a perplexing anomaly to a pressing scientific and clinical challenge demanding urgent attention. Its unique molecular profile, environmental risk factors, clinical presentation, and treatment responses diverge considerably from smoking-related lung cancer, necessitating specialized research and tailored clinical approaches. As evidence mounts, the oncology community anticipates a future where improved risk stratification, early detection, preventive interventions, and targeted therapies combine to reduce LCINS morbidity and mortality. This evolving frontier in cancer research embodies the promise of precision medicine and the ongoing quest to conquer one of the world’s deadliest diseases beyond traditional smoking paradigms.

Subject of Research: People
Article Title: Lung cancer in never smokers: from early detection to prevention
News Publication Date: 11-Feb-2026
Web References: https://www.cell.com/trends/cancer/fulltext/S2405-8033(25)00315-2
References: Caswell, D.R., Hiley, C., Murphy, C., et al. (2026). Lung cancer in never smokers: from early detection to prevention. Trends in Cancer. DOI: 10.1016/j.trecan.2025.12.009
Keywords: Lung cancer, Never-smokers, Early detection, Prevention, EGFR mutations, ALK fusions, Targeted therapy, Environmental risk factors, Genetic predisposition, Screening, Public health interventions

Genetic polymorphisms in DNA repair genes have long been suspected of modulating individual vulnerability to cancers, including lung cancer, but data concerning Latin American populations are scarce. The Cuban population, characterized by its unique genetic admixture resulting from diverse African, European, and Indigenous ancestries, presents a compelling context for investigating genetic variations associated with lung cancer risk. The study meticulously analyzed five key single nucleotide polymorphisms (SNPs) – rs1042522, rs11016879, rs13181, rs25487, and rs861539 – focusing on their frequency distribution among 300 lung cancer patients and 300 matched control subjects.

One of the standout findings involves the SNP rs1042522, located in the TP53 gene, a tumor suppressor critically involved in DNA repair and apoptosis regulation. The heterozygous genotype of this variant was associated with a notably reduced risk of developing lung cancer. This protective effect, observed under an overdominant genetic model with an odds ratio (OR) of 0.53, suggests a complex genetic interplay possibly modulating cellular DNA damage response efficacy and influencing carcinogenesis susceptibility.

Conversely, the variant rs25487 in the XRCC1 gene showed a contrasting trend. This SNP displayed an additive genetic risk pattern, signifying that each additional risk allele incrementally raised lung cancer susceptibility (OR 1.61). XRCC1 is central to the base excision repair pathway, repairing single-strand breaks in DNA; thus, alterations in this gene potentially compromise genomic stability, fostering oncogenic mutations especially in lung tissue chronically exposed to carcinogens such as tobacco smoke.

Remarkably, the genetic data revealed differential distribution patterns linked to phenotypic traits such as skin color among controls, notably for rs1042522 and rs861539. This insight underscores the importance of considering racial and ethnic genetic backgrounds as modifiers in epidemiological studies and reinforces the necessity for population-specific genetic databases in cancer genomics.

The interplay between genetic predisposition and environmental factors was further elucidated through the interaction analyses. For instance, the combined effect of rs25487 and cigarette smoking dramatically amplified lung cancer risk, illustrating how genetic vulnerability may compound the detrimental effects of tobacco carcinogens. This synergy attained statistical significance with an OR of 3.72 and a strong p-interaction value, emphasizing smoking cessation as an indispensable intervention even in genetically predisposed individuals.

Furthermore, the study unearthed a borderline significant interaction between alcohol consumption and the variant rs13181, hinting at a possible protective modification against lung cancer risk. Although the p-interaction remained slightly above strict thresholds, this finding prompts further exploration into lifestyle-genetic interplay and its mechanistic basis within DNA repair pathways.

Apart from susceptibility, the research delved into survival outcomes, assessing the impact of these polymorphisms on overall patient prognosis. Intriguingly, the alternative allele of rs11016879 emerged as an independent prognostic factor associated with increased 5-year survival rates among lung cancer patients. This polymorphism, residing in the ERCC2 gene vital for nucleotide excision repair, may enhance repair efficiency post-diagnosis or influence treatment responsiveness, representing a potential biomarker for patient stratification.

The methodological approach of the study incorporated robust statistical techniques including logistic regression for association testing and survival analyses through Kaplan-Meier and Cox regression models. These quantitative frameworks enabled precise estimation of genetic effects while accounting for covariates such as demographic factors and lifestyle exposures, thereby strengthening the validity of the conclusions.

This study breaks new ground by providing the first comprehensive evaluation of DNA repair gene variants in relation to lung cancer risk and survival within a Cuban cohort. The findings accentuate the heterogeneity of genetic risk factors across populations and emphasize the critical role of incorporating ancestral genetic diversity and phenotypic attributes like skin color in cancer susceptibility research.

In the context of public health, these insights have profound implications. They call for tailored screening programs incorporating genetic risk profiles alongside environmental exposure assessments, particularly targeting high-risk groups identified by combined genetic and lifestyle factors. Moreover, such knowledge could inform personalized therapeutic strategies, optimizing treatment choices based on individual genetic repair capacity.

The research also highlights the pressing need for further explorations into how polymorphisms in DNA repair genes interact with complex environmental carcinogens, including tobacco and alcohol, under diverse genetic backgrounds. Such studies are essential for unraveling the multifactorial nature of lung cancer development and progression.

As lung cancer continues to impose a massive global health burden, especially in regions with high smoking prevalence and genetic admixture like Cuba, this investigation sets a valuable precedent. It demonstrates that genetic epidemiology, when integrated thoughtfully with population characteristics, can provide actionable insights for early detection, prevention, and clinical management.

Ultimately, this investigation into the Cuban population underscores how the convergence of genetic polymorphisms and environmental exposures orchestrate lung cancer risk and outcomes. It is a clarion call for expanding genomic research across diverse populations, moving beyond European-centric studies, to achieve equitable advancements in cancer care worldwide.

The study’s novel findings herald a new era for cancer genetics in Latin America, paving the way for personalized medicine approaches grounded in the molecular landscape of populations historically underrepresented in research. As more comprehensive genetic and environmental data are accumulated, the hope is to translate these discoveries into tangible clinical benefits, improving survival and quality of life for lung cancer patients everywhere.

Subject of Research: Genetic polymorphisms in DNA repair related genes and their association with lung cancer susceptibility and survival prognosis in the Cuban population

Article Title: Polymorphisms in DNA repair related genes as risk factors for lung cancer in Cuban population: a case control study

Article References:
Reyes-Reyes, E., Cuétara-Lugo, E., Herrera-Isidrón, J.A. et al. Polymorphisms in DNA repair related genes as risk factors for lung cancer in Cuban population: a case control study. BMC Cancer 25, 1717 (2025). https://doi.org/10.1186/s12885-025-15072-1

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15072-1